Skip directly to site content Skip directly to search


Español  Other Languages


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
 Search

		Submit


Tuberculosis (TB)








National TB Performance Targets							Updated November 21, 2022
																	Related Pages
										Return to Main MenuWhat is the difference between indicators, objectives, and performance targets?
**What are national TB performance targets?**
Every five years, CDC updates national performance targets for Tuberculosis (TB) programs in the United States (U.S.). These targets were developed to track U.S. TB program progress toward TB elimination. The 2025 National TB Program Objectives & Performance Targets table [PDF – 106 KB] lists all current objectives and targets.
National TB Performance targets are measurable and aspirational and are intended to be used by TB programs to assess their level of performance in achieving national program objectives. In short, they are longer-term goals to work toward.
**Should all programs expect to achieve the National Performance Target by the target year?**
Targets are set using historical data and do not consider program resources or local TB epidemiology. Programs should aim for steady progress to achieve targets. While TB programs should make efforts to reach targets, the targets are not annual TB program requirements. Achieving the National Performance Target is a marathon, not a sprint.
Regular performance monitoring and program evaluation can help TB programs document their progress. Programs can use the National TB Indicators Project (NTIP) as a tool to conduct routine program monitoring. NTIP provides information that is used to show how a program is performing over time and how a program is performing to reach a target. Monitoring and evaluation can help identify areas for improvement to assist TB programs in achieving the performance targets. Once a TB program identifies why it is performing well or where improvement is needed, changes can be made over time to move closer to the target. Additionally, program performance can be used to brief local leadership who may be able to provide additional input and needed resources.
**How are targets calculated?**
TB targets are calculated using national surveillance data from previous years. The target is set at a level that 10% of TB programs have already reached in the most recent reporting period with available data.
For 2025, the national TB performance targets for each national TB program objective were calculated using TB surveillance data reported to CDC from years 2010 to 2018. A quantile regression model was used to estimate the 90th percentile for each year. The fitted model was extrapolated to predict the estimated 90th percentile in the year 2018, which serves as the target for 2025. The 90th percentile values reflect the projected performance in 2018 of the top 10% of TB programs in the United States.
A quantile regression establishes a smooth trend over time, which is useful since the actual percentiles in any given year may not be representative of the overall trend. Therefore, a regression model is used to predict values (even for years that have actual data values). The predicted value is used as the future target.1 The model allows us to identify a level of performance that is a realistic target for TB programs to aim towards over the next five-year period. Although aspirational for some, at least 10% of programs have already reached this level of performance by the beginning of the five-year period, indicating that it is achievable.
Calculation of the 2025 national program target for reducing TB incidence to a rate of 1.31 per 100,000 persons or less
The following example shows the calculation of the 2025 national program target for reducing TB incidence to a rate of 1.31 per 100,000 persons or less.
Annual TB incidence data for 2010-2018 for each of the 52 reporting areas (50 states, New York City, and Washington, D.C.) are graphed to the right using black (open) circles to represent a single reporting area.
The green (colored/shaded in circles) represent the lowest 10th percentile of TB incidence in each year.
The red (solid) line is the 10th percentile regression line and smooths the estimates over the entire period. The regression line is based on the value that represents the 10th percentile and considers the trend across all the years. The predicted value for 2018 is 1.31, which is used as the 2025 target.Annual treatment completion data for the 52 reporting areas over 2010-2018
Another example shows the calculation of the 2025 national performance target of 95% of TB patients completing treatment within 12 months.
The graph at the right shows annual treatment completion data for the 52 reporting areas over 2010-2018. Notice a drop in the 10th percentile completion rate (the green circle) for 2017, but the red smoothed estimate is above it.
The predicted value (the red, solid line) is 95.06% for 2018, which is used as the 2025 target.**Notes:**
1More statistical detail: Reporting areas that have fewer than 150 cases over the entire baseline period (for example, 2010-2018) are excluded from all target calculations due to unreliable trends. Additionally, reporting areas with a non-U.S.-born population or U.S.-born non-Hispanic black or African American population less than an average of 100,000 persons per year in the most recent three-year period available are excluded in the statistical model for TB incidence rates for non-U.S.-born persons and U.S.-born non-Hispanic blacks or African Americans because the data would be too small to establish a reliable trend.
							
					
							Last Reviewed:  November 21, 2022						Source: 	Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention
					Facebook
        Twitter
        LinkedIn
        Syndicate homeTuberculosisBasic TB Factsplus iconHow TB SpreadsLatent TB Infection and TB DiseaseSigns & SymptomsTB Risk FactorsExposure to TBTB PreventionVaccinesTB & HIV CoinfectionTB and DiabetesTB TermsPersonal StoriesTesting & Diagnosisplus iconWho Should be TestedTesting for TB InfectionTesting in BCG-Vaccinated PersonsTB Screening and Testing of Health Care PersonnelTesting During PregnancyDiagnosing latent TB infection and TB diseaseTreatmentplus iconDeciding When to Treat Latent TB InfectionTreatment Regimens for Latent TB Infection (LTBI)Treatment for TB DiseaseAdverse EventsTB Treatment of Persons Living with HIVTB Treatment and PregnancyTB Treatment for ChildrenFrequently Asked QuestionsDrug-Resistant TBResearchplus iconTB Epidemiologic Studies Consortiumplus iconResearch ProjectsPublicationsTB Trials Consortiumplus iconStudy DescriptionsBackgroundBehavioral & Social Science ResearchHealth Care Settingsplus iconTB Infection Control in Health Care SettingsResources for TB Screening and Testing of Health Care Personnelplus iconFrequently Asked QuestionsTB in Specific Populationsplus iconHealth DisparitiesAsian PersonsBlack or African American PersonsHispanic or Latino PersonsChildrenPregnancyCorrectional FacilitiesPeople Experiencing HomelessnessInternational TravelersLaboratory Informationplus iconDrug Susceptibility TestingFalse-Positive Investigation ToolkitInterim Laboratory Biosafety Guidance for XDR  tuberculosis strainsModel Performance Evaluation Program (MPEP)Rapid Molecular Testing to Detect Drug-Resistant TB in the USplus iconExecutive SummaryIntroductionBackground on Tests for Molecular Detection of DRGeneral Considerations and Principles for a Molecular DR Testing ServicePossible Scenarios and Scope of Testing for a Molecular DR Testing ServiceResearch NeedsGeneral Recommendations of the Expert PanelCommunication Plan for the ReportRecommendationsReferencesPanel Members and CDC ParticipantsAppendix 1Appendix 2Appendix 3The Uses of Nucleic Acid Amplification Tests for the Diagnosis of TBplus iconGeneral ConsiderationsGeneral Recommendations of the Expert PanelRecommendations to ACET, CDC, DTBEData & Statisticsplus iconTB Incidence in the United StatesReported TB in the US, 2022 Surveillance Reportplus iconNational DataReporting Area DataRisk FactorsDemographicsTB Treatment and Case OutcomesDrug-Resistant TBMolecular SurveillanceTuberculosis in the United States, 2022 (Slide Set)Archived Surveillance Reports and Slide Sets2021 State and City ReportArchived State and City ReportsProfessional Resources & Toolsplus iconTools for Healthcare ProvidersResources for TB Programsplus iconStrengthening Civil Surgeons’ Capacity to Improve LTBI Surveillance and Outcomes Among Status AdjustersNotice of Funding Opportunity (NOFO)Program EvaluationTB Centers of ExcellenceTB Elimination AllianceTB Genotypingplus iconConventional TB GenotypingWhole Genome SequencingTB GIMSAnalytic ToolsLatent Tuberculosis Infection ResourcesPublications & Productsplus iconPatient and Public MaterialsFact SheetsGuidelinesplus iconControl & EliminationDrug-Resistant TBInfection Control & PreventionLaboratory & GenotypingTB & HIVTB in Specific PopulationsTesting & DiagnosisTreatmentVaccines & ImmunizationsArchived TB GuidelinesGuides & Toolkitsplus iconAggregate ReportsCDC TB Surveillance TrainingCore CurriculumEffective TB Interviewing for Contact InvestigationEthnographic GuidesFalse-Positive Investigation ToolkitForging Partnerships to Eliminate TuberculosisGuide to Application of GenotypingLTBI: A Guide for Primary Health Care ProvidersMantoux Tuberculin Skin Testing ProductsReport of Verified Case of Tuberculosis (RVCT)Self-Study ModulesTB Contact Investigation Interviewing Skills CourseTB eDOT ToolkitUnderstanding the TB Cohort Review ProcessNewslettersplus iconTB Notes, No. 4, 2023TB Notes, No. 3, 2023TB Notes. No. 2, 2023TB Notes. No. 1, 2023TB Notes, No. 4, 2022TB Notes, No. 3, 2022TB Notes, No. 2, 2022TB Notes, No. 1, 2022TB Notes, No. 4, 2021TB Notes, No. 3, 2021TB Notes, No. 2, 2021TB Notes, No. 1, 2021Pamphlets, Brochures, Bookletsplus iconQuestions and AnswersPatient Education SeriesTuberculosis - Get the FactsTuberculosis - The Connection between TB and HIV12-Dose Regimen for Latent TB Infection-Patient Education BrochurePostersplus iconMantoux Tuberculin Skin Test Wall ChartWorld TB DayThink TBStop TBTake on TBReports & Articlesplus iconDTBE Authored Journal ArticlesTuberculosis Laboratory Aggregate ReportsSlide Setsplus iconIntroduction to TuberculosisEpidemiology of Tuberculosis Among Non-U.S.​–Born Persons in the United States, 1993–2016Self-Study Modules on Tuberculosis, 1-5 Slide SetsThe Tuberculosis (TB) in Correctional Settingsplus iconFacilitator GuideIntroduction to TB GenotypingEpidemiology of Tuberculosis in Correctional Facilities, United States, 1993-2017Prevention and Control of Tuberculosis in Correctional and Detention FacilitiesGuidelines for Preventing the Transmission of M. TB in Health care SettingsInvestigation of Contacts of Persons with Infectious TBEpidemiology of Pediatric Tuberculosis in the United StatesTargeted Tuberculosis Testing and Treatment of Latent Tuberculosis InfectionElectronic Tools & ResourcesWeb-Based Courses & Webinarsplus iconTB 101 for Health Care WorkersContent SyndicationInfographicsplus iconSocial Media GraphicsCustomizable Take on TB Infographic with InstructionsEventsWorld TB Dayplus iconU.S. TB ChampionsHistoryFeaturesplus iconTB Risk FactorsTreating Latent TB Infection with Short-Course RegimensWorld Tuberculosis (TB) Day 2021World Tuberculosis (TB) Day 2020Linksplus iconState TB Control OfficesAbout Usplus iconMission Statement and Activitiesplus iconDTBE Strategic PlanNational TB Program ObjectivesOrganization ChartAdvisory Groupsplus iconFederal TB Task Force To receive email updates about this page, enter your email address: Email Address			What's this?				Submit


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue